Plain-English translation of NCT06634875 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new medication called , when combined with an approved immunotherapy drug (pembrolizumab), can help treat colorectal cancer that has spread or cannot be surgically removed. Colorectal cancer with certain genetic features — like a KRAS mutation and high tumor mutation burden — often doesn't respond well to standard treatments. This study hopes that combining the two medications might wake up your immune system to fight the cancer more effectively.
Many people with colorectal cancer that has these specific genetic features have already tried standard treatments without success. This medication represents a new approach — it works differently from previous treatments by targeting inflammation in a way that might help immunotherapy drugs work better — so researchers want to test whether it offers hope for people who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication () combined with the approved immunotherapy drug (pembrolizumab) over a period of time, likely through injections or infusions. You would have regular clinic visits to check how you're responding, including blood tests and imaging scans to measure your cancer. The trial involves about 20 participants total, and your doctor will monitor you closely for how well the treatment works and any side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States